Serina Therapeutics, Inc. — filing identity discrepancy
The supplied filing is AgeX Therapeutics, Inc.’s Form 10-Q, not a Serina Therapeutics filing. The summary below reflects the filing itself. It covers the quarter and six months ended June 30, 2022; financial statement amounts are in thousands of dollars unless stated otherwise.
Business context and reporting period
AgeX is a biotechnology company developing cell-based therapies and regenerative technologies. Following staff reductions and closure of its laboratory facility, it operates with a minimal workforce and relies on outsourced research and development. LifeMap Sciences was sold and deconsolidated in March 2021; its results are reported as discontinued operations.
Key financial metrics
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue from continuing operations | $12 | $37 | $17 | $93 |
| Gross profit | $6 | $24 | $10 | $77 |
| Operating expenses | $1,597 | $2,229 | $3,653 | $4,575 |
| Net loss attributable to AgeX | $2,618 | $2,474 | $5,324 | $4,562 |
| Net loss per share, basic and diluted | $0.07 | $0.07 | $0.14 | $0.12 |
| Net cash used in operating activities | — | — | $3,382 | $4,324 |
At June 30, 2022, cash and cash equivalents were $702 (plus $50 restricted cash), total assets were $2,579, and total liabilities were $15,841. Juvenescence loans had a balance-sheet carrying value, net of debt issuance costs, of $13,724: $6,968 current and $6,756 noncurrent. Stockholders’ deficit was $13,262. Accumulated deficit was $111.1 million.
Material changes versus the prior comparable period
- Revenue and gross profit declined, mainly because the NIH grant was fully expended by December 2021. Research-product revenue was $12 in Q2 and $17 for the first half of 2022, versus $26 and $36, respectively, in 2021.
- Operating expenses fell 28% in Q2 and 20% for the first half, reflecting lower research, legal, consulting, stock compensation and royalty-related costs.
- Despite lower operating expenses, first-half net loss increased to $5,324 from $4,562, largely reflecting higher interest expense and a $255 noncash loss from remeasurement of warrant liabilities. The 2021 comparison included a $437 gain from PPP loan forgiveness and a $106 gain on LifeMap deconsolidation.
- Operating cash use improved to $3,382 from $4,324 for the first half. Financing activities provided $3,500 in net cash; cash and restricted cash rose by $118 to $752.
Outlook, risks and unusual items
- Going concern: Management says available cash, remaining Juvenescence credit and potential ATM proceeds are insufficient for anticipated funding needs over the next 12 months. The filing states that substantial doubt exists about AgeX’s ability to continue as a going concern and that additional financing is needed.
- Financing and dilution: AgeX had borrowed $10.16 million of a $13.16 million secured convertible note facility; the remaining $3 million was subject to Juvenescence’s discretion. It also had $8 million outstanding under a separate 2020 loan agreement. The secured note bears fees, is convertible, and is secured by substantially all AgeX assets. Related warrants and potential conversions could materially dilute shareholders.
- Operating and development risks: Cost reductions and reliance on outsourced research have constrained development progress. COVID-19 slowed university-sponsored research; the company expected initial work to conclude during 2022. The filing provides no specific financial guidance or quantified revenue outlook.
- Listing risk: NYSE American had accepted a compliance plan, with a stated compliance date of November 17, 2022; failure to show progress or regain compliance could lead to an extended deadline or delisting proceedings.
- The filing reports no material litigation, no off-balance-sheet arrangements, and no material changes to previously disclosed risk factors other than the financing and going-concern risk. Management reported disclosure controls were effective and no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer: the provided metadata names Serina Therapeutics, but the filing identifies AgeX Therapeutics, Inc. (ticker AGE).
- Assess the company’s near-term funding runway, including the discretionary remaining Juvenescence facility, ATM availability and any subsequent financing.
- Review the secured note’s collateral, covenants, conversion terms, warrant accounting and potential dilution, including any required shareholder approvals.
- Check the status of NYSE American listing compliance and the November 17, 2022 deadline.
- Evaluate whether the reduced-cost, outsourced research model can support meaningful development progress and potential licensing or other funding.